"Eli Lilly Polska" Sp. z o.o. (Poland)

Eli Lilly Polska functions as the Polish affiliate of the global pharmaceutical company Eli Lilly, focused on commercialization, medical and patient support activities for prescription medicines across prioritized therapeutic areas. The operating model centers on marketing authorization lifecycle support, market access and stakeholder engagement, medical education and scientific exchange, and distribution coordination for branded therapeutics and specialty medicines. Business focus areas align with the groups global priorities, including treatments for diabetes and cardiometabolic conditions, oncology, immunology and selected neuroscience-related indications, supported by clinical research engagement and collaboration with the healthcare ecosystem where applicable. Geographic scope is national, serving the Polish healthcare market through relationships with healthcare professionals, hospitals, payers and distribution partners while leveraging global R&D, manufacturing and quality systems from the parent organization. Key assets include the Lilly product brand portfolio, clinical and regulatory expertise, and medical-scientific capabilities supporting evidence-based adoption and appropriate use. Strategic positioning is centered on innovation-driven specialty and chronic disease therapeutics, portfolio development around high-unmet-need areas, and long-term engagement in improving patient outcomes through medicines and supporting services aligned to Polish market requirements.